Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Celltrion Inc (068270 KS)
Watchlist
721
Analysis
Health Care
•
South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Cross Asset Strategy
•
14 Jun 2021 20:08
KRX Plans to Launch a New Index Called 'KOSPI 200 Top 10'
According to the KRX, it plans to launch new indices which would include the top 10 stocks in KOSPI. The name of this index is expected to be...
Douglas Kim
Follow
416 Views
Share
bullish
•
Cross Asset Strategy
•
10 Apr 2021 16:14
NPS Raises Domestic Equity Allocations
NPS increased the strategic asset allocation (SAA) limit for domestic equities from the current 2% to 3%. As a result of this change, the sale of...
Douglas Kim
Follow
575 Views
Share
bearish
•
Quantitative Analysis
•
05 Jul 2026 10:20
KRX Foreign Holding Weekly (Jul 3rd): Samsung Electronics, SK Hynix, SKSQUARE, SamsungElecMech
We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Samsung Electronics, SK Hynix, SKSQUARE,...
Ke Yan, CFA, FRM
Follow
121 Views
Share
bearish
•
Cross Asset Strategy
•
03 Feb 2021 20:02
PARTIAL END of Ban on Short Selling of Stocks in Korea
Korea Financial Services Commission (FSC) announced after the market close today that there will be a PARTIAL end of the ban on short selling of...
Douglas Kim
Follow
478 Views
Share
bullish
•
Thematic (Sector/Industry)
•
07 Dec 2020 20:41
The Stocks to Own in Asia – Vol. 31
The Stocks to Own in Asia – Vol. 31. We highlight 14 stocks in Asia that look interesting to us based upon our FVMR Methodology.
A. Stotz Investment Research
Follow
414 Views
Share
First
Previous
18
19
20
21
22
23
24
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.5
x